[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634166":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":32,"locations":33,"responsibleParty":54,"collaborators":58,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":32,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":36,"whyStopped":32,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Kasr El Aini Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Antihistamine","ACTIVE_COMPARATOR","chlorpheniramine 0.25 mg\u002FKg in 2 ml",[13],"Drug: Antihestamine",{"label":15,"type":16,"description":17,"interventionNames":18},"control","PLACEBO_COMPARATOR","equal volume of normal saline",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Antihestamine","chlorpheniramine 0.25 mg\u002FKg in 2 ml immediately after separation from CPB, before protamine administration",[9],[27],"chlorpheniramine",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","equal volume normal saline",[15],null,[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Misr Universty for Scince and Technology","RECRUITING","Giza","October","12582","Egypt","EG",{"type":43,"coordinates":44},"Point",[45,46],31.20861,30.00944,{"lat":46,"lon":45},[49],{"name":50,"role":51,"phone":52,"phoneExt":32,"email":53},"Ahmed Mohamed Elhaddad, Assisstant Professor","CONTACT","0201224042847","drblacksmith5@kasralainy.edu.eg",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Ahmed Mohamed Mohamed Elhaddad","assisstant professor",[59],{"name":60,"class":6},"Misr University for Science and Technology","100634166","phase-4-antihistamine-for-prevention-of-htr-after-blood-primed-cpb-100634166",false,"NCT07536152","Antihistamine for Prevention of HTR After Blood Primed CPB","Prophylactic Antihistamine for Prevention of Hypotensive Transfusion Reaction After Blood Primed Cardiopulmonary Bypass in Pediatric Cardiac Surgery: a Randomized-controlled Study","HTR - CPB","Inclusion Criteria:\n\n* Acyanotic congenital heart disease.\n* Age :1 -7 years.\n* Genre: both.\n\nExclusion Criteria:\n\n* Redo patient.\n* History of allergy to antihistamines.\n* Bleeding disorders with INR \\> 1.5 and\u002For platelets \\\u003C 50,000.\n* Emergency procedure.","ALL","1 Year","7 Years",{"count":73,"type":74},40,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","This study will be a randomized, double-blinded, placebo-controlled study conducted at a university hospital. Forty children undergoing elective repair of a congenital heart defect will be included. The patients will be randomly allocated (20 patients per group) to receive a single intravenous dose of combined chlorpheniramine or normal saline immediately after separation from CPB, before protamine administration.",[80],"Blood Transfusion Associated Adverse Reactions",[82],"prevention of hypotensive transfusion reaction","2026-04-16",{"date":85,"type":86},"2026-04-21","ACTUAL",{"date":88,"type":86},"2026-03-01",{"date":90,"type":74},"2026-12",{"name":5,"class":6},1]